Your browser version may not work well with NCBI's Web applications. More information here...
1: Expert Opin Pharmacother. 2007 May;8(7):923-33.Click here to read Links

Access denied? The status of co-receptor inhibition to counter HIV entry.

Biswas P, Tambussi G, Lazzarin A.

San Raffaele Scientific Institute, Lab. of Clinical Immunology, Via Stamira d'Ancona n. 20, Milan, Italy. biswas.proscilla@hsr.it

As resistance and long-term metabolic abnormalities hamper the efficacy of previous drugs against HIV-1, targeting of HIV co-receptors represents an exciting new frontier for antiretroviral therapeutics. CCR5 inhibitors are most likely to be the new available drugs within the class of entry inhibitors. This paper reviews the most recent clinical data available on the small-molecule compounds vicriviroc and maraviroc and on the antibodies PRO 140 and CCR5mAb004, as well as some novel genetic approaches. A thorough overview of the many challenges, past, present and future, that CCR5 inhibitors encounter during their development pathway is then presented. Possible immunologic consequences are also discussed. It could be foreseen that the benefit for HIV-infected individuals derived by the use of these potential novel drugs will outweigh the costs/risks intrinsically present in every new therapeutic approach.

PMID: 17472538 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Maraviroc (Selzentry® )

    Maraviroc is used with other medications to treat human immunodeficiency virus (HIV) in patients with or without acquired immunodeficiency syndrome (AIDS). Maraviroc is in a class of antiviral medications called CCR5 co-...

  • Source: AHFS Consumer Medication Information